3.3 Mast cell degranulating (MCD) peptide Mast cell degranulating (MCD) Peptide, or peptide 401, is a BV polypeptide of 22 amino acids equivalent to apamin because it has two disulfide bridges (Rsinar et al., 2023)
These peptides are popular for their benefits in muscle growth, fat loss, injury recovery, and overall enhancement of physical performance
This can be due to weakening of the stomach lining, or to medications that reduce stomach acid
The twenty-six week completion rate in Study 2 was 74%
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al